SCHEMBL1693604

SCHEMBL1693604

O=c1[nH]c2cnc(Cl)nc2n1C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR1 Q9BXC0 2/20 0.50
JAK2 O60674 9/20 0.49
JAK3 P52333 9/20 0.49
JAK1 P23458 6/20 0.49
MTOR P42345 1/20 0.46
MAP3K11 Q16584 1/20 0.44
CCNE2 O96020 3/20 0.44
CCNE1 P24864 3/20 0.44
CDK2 P24941 3/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA2B P29275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501865 1.00 HCAR1 (0.50) HCAR1JAK2JAK3JAK1MTOR
SCHEMBL1781369 0.99 HCAR1 (0.48) HCAR1JAK2JAK3JAK1MTOR
SCHEMBL21593673 0.88 JAK2 (0.43) HCAR1JAK2JAK3JAK1MAP3K11
SCHEMBL29770995 0.88 JAK2 (0.47) HCAR1JAK2JAK3JAK1CCNE2
SCHEMBL20299440 0.88 JAK2 (0.47) HCAR1JAK2JAK3JAK1CCNE2
SCHEMBL23974060 0.86 JAK2 (0.44) HCAR1JAK2JAK3JAK1CCNE2
SCHEMBL1693606 0.86 JAK2 (0.59) JAK2JAK3JAK1MTORCHRM2
SCHEMBL23929312 0.86 JAK2 (0.44) HCAR1JAK2JAK3JAK1CCNE2
SCHEMBL20329966 0.86 JAK2 (0.54) JAK2JAK3JAK1MTORMAP3K11
SCHEMBL23452644 0.86 JAK2 (0.54) JAK2JAK3JAK1MTORMAP3K11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124492-A1 Amino-triazolopyridine Compounds and Their Use in Treating Cancer ASTRAZENECA AB (SE) 2024-04-18 US disclosed
CN-114315834-B Imidazolone derivatives and their use in medicine 成都百裕制药股份有限公司 2024-01-05 CN disclosed
US-11746118-B2 Amino-triazolopyridine compounds and their use in treating cancer ASTRAZENECA AB (SE) 2023-09-05 US disclosed
US-11746118-B2 Amino-triazolopyridine compounds and their use in treating cancer ASTRAZENECA AB (SE) 2023-09-05 US disclosed
US-11746118-B2 Amino-triazolopyridine compounds and their use in treating cancer ASTRAZENECA AB (SE) 2023-09-05 US disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
CN-113121538-B Furan derivative and application thereof in medicine 成都百裕制药股份有限公司 2023-04-21 CN disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-103649085-A Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases ALMIRALL SA 2014-03-19 CN disclosed
EP-2582703-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2013-04-24 EP disclosed
US-20130089512-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-04-11 US disclosed
US-20130089512-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-04-11 US disclosed
US-20130089512-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-04-11 US disclosed
WO-2012160030-A1 PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES ALMIRALL, S.A. (ES) 2012-11-29 WO disclosed
WO-2011157397-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-12-22 WO disclosed
WO-2011157397-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-12-22 WO disclosed
EP-2397482-A1 Heteroaryl imidazolone derivatives as jak inhibitors Almirall, S.A. (ES) 2011-12-21 EP disclosed
EP-2397482-A1 Heteroaryl imidazolone derivatives as jak inhibitors Almirall, S.A. (ES) 2011-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124492-A1 Amino-triazolopyridine Compounds and Their Use in Treating Cancer DCK, TYMP, DPYD HCAR1 3591/4885JAK2 257/4885JAK3 884/4885
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 HCAR1 1040/4885JAK2 537/4885JAK3 599/4885
US-11746118-B2 Amino-triazolopyridine compounds and their use in treating cancer DCK, TYMP, DPYD HCAR1 3591/4885JAK2 257/4885JAK3 884/4885
US-20130089512-A1 HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS JAK2, JAK1, JAK3 HCAR1 4260/4885JAK2 1/4885JAK3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.